ClinicalTrials.Veeva

Menu

Prevention of Intrauterine Growth Retardation in Burkina Faso: the Malaria Component

I

Institute of Tropical Medicine, Belgium

Status and phase

Completed
Phase 4

Conditions

Malaria
Malaria in Pregnancy

Treatments

Drug: Chloroquine (CQ)
Dietary Supplement: Multiple micronutrients supplements (MMS)
Drug: Sulphadoxyne-pyrimethamine (SP)
Dietary Supplement: Iron and folic acid (IFA)

Study type

Interventional

Funder types

Other

Identifiers

NCT00680732
IUGR Malaria

Details and patient eligibility

About

Our objective was to investigate the importance of malaria infection/disease during pregnancy and more particularly during the first trimester; we also looked at the maternal-foetal interactions and their influence on the subsequent child's response to malaria infections during the first year of life. This study was carried out !in the same population recruited for the IUGR study (NCT00642408).

Full description

A research project aiming at investigating the impact of multivitamin-mineral supplementation (MMS) during pregnancy on intra-uterin growth retardation was carried out in the Hounde district, an area not far from the Centre Muraz located in Bobo Dioulasso, and where malaria is endemic. Malaria during pregnancy increases the risk of low birth weight, infant mortality and morbidity during the first year of life by inducing growth retardation, prematurity and infant anaemia.

The administration of an antimalarial drug during pregnancy has a beneficial effect on the mother and child's health by preventing malaria infection and its consequences. However, most studies have been carried out during the second or third trimester of pregnancy: the effect of malaria infection during the first trimester on the mother's and child's health is unknown. It has been reported that even one single infection may have a significant impact on the outcome of pregnancy: if it is true, then early chemoprophylaxis may have an additional advantage.

An alternative approach is the administration of intermittent presumptive treatment, which may achieve equal efficacy to continuos chemoprophylaxis; however, no studies compared effective weekly malaria chemoprophylaxis with effective intermittent presumptive treatment. Moreover, the incidence of malaria clinical episodes during SP intermittent preventive treatment has never been investigated.

Therefore, this open label, factorial study was carried out in the same women recruited for the IUGR nutritional study (NCT00642408). Women receiving multiple micronutrients supplements (MMS) or dietary supplements (IFA) were further randomised in 2 groups: CQ weekly chemoprophylaxis or SP intermittent preventive treatment. The administration of treatment was directly observed.

Enrollment

1,370 patients

Sex

Female

Ages

15 to 44 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • 15 to 44 years
  • females
  • living in the study area

Exclusion criteria

  • planning to move outside the district within two years
  • regularly using a contraceptive methods
  • already pregnant at the start of the trial

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Factorial Assignment

Masking

None (Open label)

1,370 participants in 4 patient groups

A1
Experimental group
Description:
Multiple micronutrients supplements (MMS) and weekly chloroquine (CQ)
Treatment:
Dietary Supplement: Multiple micronutrients supplements (MMS)
Drug: Chloroquine (CQ)
A2
Experimental group
Description:
Multiple micronutrients supplements (MMS) and intermittent suplphadoxyne-pyrimethamine (SP)
Treatment:
Drug: Sulphadoxyne-pyrimethamine (SP)
Dietary Supplement: Multiple micronutrients supplements (MMS)
B1
Experimental group
Description:
Iron and folic acid (IFA) and weekly chloroquine (CQ)
Treatment:
Dietary Supplement: Iron and folic acid (IFA)
Drug: Chloroquine (CQ)
B2
Experimental group
Description:
Iron and folic acid (IFA) and intermittent sulphadoxyne-pyrimethamine (SP)
Treatment:
Dietary Supplement: Iron and folic acid (IFA)
Drug: Sulphadoxyne-pyrimethamine (SP)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems